Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - fludarabine phosphate, quantity: 50 mg - injection, powder for - excipient ingredients: mannitol; sodium hydroxide - treatment of b-cell chronic lymphocytic leukaemia

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - clindamycin phosphate, quantity: 1.188 % w/w - gel - excipient ingredients: propylene glycol; sodium hydroxide; purified water; hyetellose; ethanol; zinc acetate - zindaclin is indicated for the treatment of acne vulgaris, particularly forms in which comedones, papules and pustules predominate.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - sonidegib phosphate, quantity: 280.8 mg (equivalent: sonidegib, qty 200 mg) - capsule, hard - excipient ingredients: colloidal anhydrous silica; magnesium stearate; purified water; gelatin; lactose monohydrate; titanium dioxide; iron oxide red; sodium lauryl sulfate; poloxamer; crospovidone; butylated hydroxytoluene; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - odomzo is indicated for the treatment of adult patients with:,- locally advanced basal cell carcinoma (bcc) who are not amenable to curative surgery or radiation therapy.,- metastatic bcc

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - clindamycin phosphate, quantity: 714 mg (equivalent: clindamycin, qty 600 mg) - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; disodium edetate - clindamycin viatris is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.,clindamycin viatris is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - clindamycin phosphate, quantity: 357 mg (equivalent: clindamycin, qty 300 mg) - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; disodium edetate - clindamycin viatris is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.,clindamycin viatris is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - oseltamivir phosphate, quantity: 7.88 mg/ml (equivalent: oseltamivir, qty 6 mg/ml) - oral liquid, powder for - excipient ingredients: saccharin sodium; sodium benzoate; sodium dihydrogen citrate; sorbitol; titanium dioxide; xanthan gum; flavour - tamiflu is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,tamiflu is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir acid - unii:k6106lv5q8) - oseltamivir carboxylate 75 mg - oseltamivir phosphate capsules are indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate capsules are indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate capsules are not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules [see microbiology (12.4)]. -  oseltamivir phosphate capsules are not recom

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir carboxylate - unii:k6106lv5q8) - oseltamivir carboxylate 75 mg - oseltamivir phosphate capsules, usp are indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate capsules, usp are indicated for the prophylaxis of influenza a and b in patients 1 year and older. oseltamivir phosphate capsules are contraindicated in patients with known serious hypersensitivity to oseltamivir or any component of the product. severe allergic reactions have included anaphylaxis and serious skin reactions including toxic epidermal necrolysis, stevens-johnson syndrome, and erythema multiforme [see warnings and precautions (5.1)] . pregnancy category c   risk summary there are no adequate and well-controlled studies with oseltamivir phosphate capsules in pregnant women. available published epidemiological data suggest that oseltamivir phosphate capsules, taken in any trimester, is not associated with an increased risk of birth defects. however, these

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu; von willebrand factor, quantity: 1200 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu; von willebrand factor, quantity: 600 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.